Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125493991 | 12549399 | 1 | I | 20160624 | 20160712 | 20160712 | PER | US-009507513-1606USA012788 | MERCK | 0.00 | M | Y | 0.00000 | 20160712 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125493991 | 12549399 | 1 | PS | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | Oral | U | 21995 | FILM-COATED TABLET | |||||||||
125493991 | 12549399 | 2 | C | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | 1 | U | 0 | |||||||||||
125493991 | 12549399 | 3 | C | GLIMEPRID | GLIMEPIRIDE | 1 | U | 0 | |||||||||||
125493991 | 12549399 | 4 | C | GLUCOPHAGE | METFORMIN HYDROCHLORIDE | 1 | U | 0 | |||||||||||
125493991 | 12549399 | 5 | C | VICTOZA | LIRAGLUTIDE | 1 | U | 0 | |||||||||||
125493991 | 12549399 | 6 | C | TOUJEO | INSULIN GLARGINE | 1 | U | 0 |
Indications of drugs used
no results found |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125493991 | 12549399 | Blood glucose increased | |
125493991 | 12549399 | Glycosylated haemoglobin decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |